Outlook Therapeutics® to Participate in the Cantor Fitzgerald Medical & Aesthetic Dermatology, Ophthalmology & Medtech Conference

December 1, 2022

https://www.globenewswire.com/news-release/2022/12/01/2565934/0/en/Outlook-Therapeutics-to-Participate-in-the-Cantor-Fitzgerald-Medical-Aesthetic-Dermatology-Ophthalmology-Medtech-Conference.html

ISELIN, N.J., Dec. 01, 2022 (GLOBE NEWSWIRE) — Outlook Therapeutics, Inc. (Nasdaq:OTLK), a biopharmaceutical company working to develop and launch the first FDA-approved ophthalmic formulation of bevacizumab for use in retinal indications, today announced that Russ Trenary, President and Chief Executive Officer of Outlook Therapeutics, will participate in a panel discussion titled, “Take A Look At What’s In Store For Wet AMD & Related Diabetic Eye Diseases,” at the Cantor Fitzgerald Medical & Aesthetic Dermatology, Ophthalmology & Medtech Conference on Thursday, December 8, 2022 at 2:45 PM ET.

Read more at globenewswire.com

Related news for (OTLK)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.